AZTherapies Revenue and Competitors
Estimated Revenue & Valuation
- AZTherapies's estimated annual revenue is currently $1.2M per year.
- AZTherapies's estimated revenue per employee is $100,500
- AZTherapies's total funding is $99.8M.
Employee Data
- AZTherapies has 12 Employees.
- AZTherapies grew their employee count by -8% last year.
AZTherapies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | FOUNDER, CEO & CHAIRMAN | Reveal Email/Phone |
2 | President and Chief Medical Officer | Reveal Email/Phone |
3 | Associate Director Clinical Operations | Reveal Email/Phone |
AZTherapies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is AZTherapies?
AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company developing treatments for devastating neurological conditions. We are using an innovative, multi-modal approach that recognizes neuro-inflammation as a root cause of neuro-degeneration, leveraging the ability of cromolyn, a small molecule with a well-characterized safety profile, to shift the brainￃﾢ￢ﾂﾬ￢ﾄﾢs innate immune cells from a pro-inflammatory to neuroprotective state. We are advancing a pipeline of candidates in Alzheimer's Disease, amyotrophic lateral sclerosis (ALS) and post-ischemic stroke cognitive impairment.
keywords:N/A
$99.8M
Total Funding
12
Number of Employees
$1.2M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AZTherapies News
Brian Bartlett is the new chief financial officer at fintech company Aliaswire. Most recently, Bartlett was CFO at biotech AZTherapies.
AZTherapies, Inc., a Boston, MA-based biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, closed a $33.6m Series C-1 financing. This C-1 round follows the receipt earlier this year of an additional $11.2m from the company’s previously announced Series C Pr ...
BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the closing of a $33.6 million Series C-1 Preferred Stock financing. This C-1 round follows the receipt earlier this year of ...
BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the closing of a $33.6 million Series C-1 Preferred Stock financing. This C-1 round follows the receipt earlier this year of ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 12 | 0% | $101.2M |
#2 | $1M | 12 | N/A | N/A |
#3 | $1M | 12 | N/A | N/A |
#4 | $1M | 12 | N/A | N/A |
#5 | $1M | 12 | N/A | N/A |